Glenmark Pharma gets USFDA nod for overactive bladder treatment drug

Glenmark Pharma gets USFDA nod for overactive bladder treatment drug Glenmark Pharmaceuticals Inc., USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Solifenacin Succinate tablets in the strengths of 5 mg and 10 mg," the company said in a BSE filing.

No comments:

Post a Comment